Login / Signup

Increase of immunoglobulin A during ibrutinib therapy reduces infection rate in chronic lymphocytic leukemia patients.

Ramona CassinAndrea VisentinDiana GiannarelliAlessandro NotoFrancesca Romana MauroLuca BaldiniLivio TrentinGianluigi Reda
Published in: Hematological oncology (2020)
Keyphrases
  • chronic lymphocytic leukemia
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • peritoneal dialysis
  • stem cells
  • mesenchymal stem cells
  • cell therapy